Original Article
Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma
Zhou Bangjian, Wang Wansheng, Yin Yu, Yang Jun, Zhu Xiaoli, Ni Caifang
Published 2024-08-01
Cite as Chin J Intern Med, 2024, 63(8): 769-775. DOI: 10.3760/cma.j.cn112138-20231102-00287
Abstract
ObjectiveTo evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma (ICC).
MethodsThe clinical data of 12 patients with unresectable ICC who received HAIC combined with lenvatinib and tislelizumab in the First Affliated Hospital of Soochow University from October 2021 to April 2023 were retrospectively analyzed. HAIC included gemcitabine plus oxaliplatin; this regimen was combined with lenvatinib and tislelizumab within 3-7 days after its initial administration. Relevant laboratory examinations were performed before each cycle of HAIC, and enhanced computed tomography/magnetic resonance imaging examinations were performed every 6-9 weeks. Tumor response to treatment was evaluated using the modified Response Evaluation Criteria in Solid Tumors. The objective response rate, disease control rate, progression-free survival, overall survival, and treatment-related adverse reactions of patients with ICC were statistically analyzed.
ResultsThe objective response rate to HAIC combined with lenvatinib and tislelizumab was 6/12; the disease control rate was 8/12; the median progression-free survival was 11.8 months; and the median overall survival was 14.2 months. Three patients had grade Ⅳ adverse reactions (increased alanine aminotransferase and aspartate aminotransferase thrombocytopenia), while three patients had grade Ⅲ adverse reactions (increased total bilirubin, alanine aminotransferase, and aspartate aminotransferase). The remaining patients had grade Ⅰ-Ⅱ adverse reactions. There were no serious complications related to interventional surgery.
ConclusionsUse of HAIC (gemcitabine plus oxaliplatin) combined with lenvatinib and tislelizumab in the treatment of unresectable ICC may be safe and feasible. Preliminary clinical studies have shown that this combination can improve the survival and prognosis of patients with ICC.
Key words:
Bile duct neoplasms; Chemotherapy, cancer, regional perfusion; Bile ducts, intrahepatic; Vntineoplastic combined chemotherapy protocols
Contributor Information
Zhou Bangjian
Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China
Wang Wansheng
Department of Interventional Radiology, Kunshan First People′s Hospital,Suzhou 215300, China
Yin Yu
Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China
Yang Jun
Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China
Zhu Xiaoli
Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China
Ni Caifang
Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006,China
